News and Events

News

All categories

Earnings

Press Release

All years

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress

November 10, 2021

Affimed to Present at Upcoming Investor Conferences

November 9, 2021

Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Autologous NK Cell Product SNK01

November 8, 2021

Affimed Announces New Innate Cell Engager AFM28 Targeting CD123 to Treat Acute Myeloid Leukemia

November 4, 2021

Affimed Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition and Company-sponsored Event on AFM13

November 4, 2021

Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021

October 29, 2021

Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

October 1, 2021

Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

September 8, 2021

Affimed to Present at Upcoming Investor Conferences

August 26, 2021

Affimed to Present at Upcoming Investor Conferences

August 26, 2021

Events

All

Scientific

Investors

02Jun

ASCO Annual Meeting

June 2 - 6, 2023 (Chicago, US)

08Jun

EHA

June 8 - 11, 2023 (Frankfurt, Germany)

13Jun

17-ICML

June 13 - 17, 2023 (Lugano, Switzerland)

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress

Affimed to Present at Upcoming Investor Conferences

Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Autologous NK Cell Product SNK01

Affimed Announces New Innate Cell Engager AFM28 Targeting CD123 to Treat Acute Myeloid Leukemia

Affimed Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition and Company-sponsored Event on AFM13

Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021

Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

Affimed to Present at Upcoming Investor Conferences

Affimed to Present at Upcoming Investor Conferences

Events

ASCO Annual Meeting

EHA

17-ICML